These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 30275099

  • 1. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
    Batenchuk C, Albitar M, Zerba K, Sudarsanam S, Chizhevsky V, Jin C, Burns V.
    J Clin Pathol; 2018 Dec; 71(12):1078-1083. PubMed ID: 30275099
    [Abstract] [Full Text] [Related]

  • 2. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M, Juco J, Huang L, Hofman V, Khambata-Ford S, Hofman P.
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [Abstract] [Full Text] [Related]

  • 3. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V, Hofman P.
    PLoS One; 2017 Apr; 12(8):e0183023. PubMed ID: 28797130
    [Abstract] [Full Text] [Related]

  • 4. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A, Barberis M, Franco R, De Luca G, Pace MV, Staibano S, Volante M, Buttitta F, Guerini-Rocco E, Righi L, D'antuono T, Scagliotti GV, Pinto C, De Rosa G, Papotti M.
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [Abstract] [Full Text] [Related]

  • 5. Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types.
    Krigsfeld GS, Prince EA, Pratt J, Chizhevsky V, William Ragheb J, Novotny J, Huron D.
    J Clin Pathol; 2020 Oct; 73(10):656-664. PubMed ID: 32591352
    [Abstract] [Full Text] [Related]

  • 6. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
    Skov BG.
    Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):49-55. PubMed ID: 31913160
    [Abstract] [Full Text] [Related]

  • 7. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS.
    J Clin Oncol; 2017 Dec 01; 35(34):3867-3876. PubMed ID: 29053400
    [Abstract] [Full Text] [Related]

  • 8. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    Vainer G, Huang L, Emancipator K, Nuti S.
    PLoS One; 2023 Dec 01; 18(6):e0285764. PubMed ID: 37267266
    [Abstract] [Full Text] [Related]

  • 9. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
    Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, Mistry A, Kalamegham R, Averbuch S, Novotny J, Rubin E, Emancipator K, McCaffery I, Williams JA, Walker J, Longshore J, Tsao MS, Kerr KM.
    J Thorac Oncol; 2017 Feb 01; 12(2):208-222. PubMed ID: 27913228
    [Abstract] [Full Text] [Related]

  • 10. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G.
    Hum Pathol; 2019 May 01; 87():11-17. PubMed ID: 30794891
    [Abstract] [Full Text] [Related]

  • 11. Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
    Fujimoto D, Yamashita D, Fukuoka J, Kitamura Y, Hosoya K, Kawachi H, Sato Y, Nagata K, Nakagawa A, Tachikawa R, Date N, Sakanoue I, Hamakawa H, Takahashi Y, Tomii K.
    Anticancer Res; 2018 Dec 01; 38(12):6891-6895. PubMed ID: 30504406
    [Abstract] [Full Text] [Related]

  • 12. A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform.
    Neuman T, London M, Kania-Almog J, Litvin A, Zohar Y, Fridel L, Sandbank J, Barshak I, Vainer GW.
    J Thorac Oncol; 2016 Nov 01; 11(11):1863-1868. PubMed ID: 27664534
    [Abstract] [Full Text] [Related]

  • 13. Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.
    Naso JR, Wang G, Banyi N, Derakhshan F, Shokoohi A, Ho C, Zhou C, Ionescu DN.
    Ann Diagn Pathol; 2021 Feb 01; 50():151590. PubMed ID: 33157383
    [Abstract] [Full Text] [Related]

  • 14. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, Fazlollahi L, Stoopler MB, Sonett JR, Sacher AG, Shu CA, Rizvi NA, Saqi A.
    Cancer Cytopathol; 2017 Dec 01; 125(12):896-907. PubMed ID: 29024471
    [Abstract] [Full Text] [Related]

  • 15. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B, Wang WL, Gong Y, Zhao J, Kalhor N, Prieto V, Staerkel G, Roy-Chowdhuri S.
    Cancer Cytopathol; 2018 May 01; 126(5):342-352. PubMed ID: 29499101
    [Abstract] [Full Text] [Related]

  • 16. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
    Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba II.
    JAMA Oncol; 2017 Aug 01; 3(8):1051-1058. PubMed ID: 28278348
    [Abstract] [Full Text] [Related]

  • 17. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
    Savic S, Berezowska S, Eppenberger-Castori S, Cathomas G, Diebold J, Fleischmann A, Jochum W, Komminoth P, McKee T, Letovanec I, Jasarevic Z, Rössle M, Singer G, von Gunten M, Zettl A, Zweifel R, Soltermann A, Bubendorf L.
    Virchows Arch; 2019 Jul 01; 475(1):67-76. PubMed ID: 31127385
    [Abstract] [Full Text] [Related]

  • 18. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB.
    J Thorac Oncol; 2017 May 01; 12(5):878-883. PubMed ID: 28104537
    [Abstract] [Full Text] [Related]

  • 19. Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.
    Velcheti V, Patwardhan PD, Liu FX, Chen X, Cao X, Burke T.
    PLoS One; 2018 May 01; 13(11):e0206370. PubMed ID: 30408065
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.